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ABSTRACT 
Objectives: TNF is one of the key cytokines involved in cancer development. TNF signaling can result in both stimulating and 
inhibitory signals that can result in opposite biological effects in cancerogenesis. 2-(1-adamantylamino)-6-methylpyridine 
(AdAMP) enhances TNF secretion whereas N-a-tosyl-L-phenylalanine chloromethyl ketone (TPCK) is a NF-κB inhibitor po-
tentially stimulating proapoptotic TNF signals. The aim of the study was to assess the effect of TPCK in combination with 
AdAMP on human ovarian cells.
Material and methods: CAOV-1 human ovarian cell line was incubated with TPCK and AdAMP for 24 hours. The cytotoxic 
effect was evaluated in a crystal violet assay. A monoclonal antibody against TNF, Infliximab, was added to examine the 
possible mechanism of interactions. 
Results: Depending on concentration, AdAMP potentialized cytotoxic activity of TPCK or had a synergistic effect with 
TPCK. Infliximab did not reverse cytotoxicity of AdAMP and TPCK and in some cytotoxic and non-cytotoxic concentrations 
even enhanced their cytotoxicity. 
Conclusions: AdAMP and TPCK cytotoxicity seems to be dependent on TNF signaling, however, the exact mechanism of 
interactions remains unclear.
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INTRODUCTION
Ovarian cancer remains the main cause of mortal-
ity among malignancies of female reproductive tract in 
developed countries [1]. Unsatisfactory survival rates are 
associated with late diagnosis and in consequence with 
inadequate treatment [2]. Contemporary management of 
advanced ovarian cancers usually includes cytoreductive 
surgery combined with adjuvant platinium-taxane based 
chemotherapy. Although the response rate in the first line 
treatment is relatively high, relapses account for about 70% 
of cases [3]. Treatment of recurrent ovarian cancer that is 
based mainly on various chemotherapy regimen poses 
a problem of drug resistance, drug toxicity and decreased 
quality of life what in turn is the limitation of further treat-
ment options and decreases overall survival [4]. Thus, in-
tervention with chemopreventive agents or new adjuvant 
therapy may offer a desirable option for the improvement 
in ovarian cancer management [5].
TNF is a multipotent cytokine that plays an important 
role in cancer growth regulation. The main source of TNF 
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are macrophages and monocytes but this cytokine can also 
be secreted by other cells including human ovarian cancer 
cells [6]. A biological effect of TNF is a result of stimula- 
ting and inhibitory signals that can give opposite results in 
different conditions. TNF-R1 is involved in most pathways, 
whereas signaling through TNF-R2 is less understood [7].
The pleiotropic actions of TNF range from proliferative 
responses such as cell growth and differentiation, through 
inflammatory effects and the mediation of immune respons-
es, to destructive cellular outcomes such as apoptotic and 
necrotic cell death mechanisms [8]. Procaspase-8 activation 
is the essential pathway of TNF induced apoptosis, whereas 
there are two arms of proliferative signals transducing that 
ultimately result in the activation of two major transcription 
factors: NF-κB and c-Jun. The existence of extensive cross 
talk between apoptosis, NF-κB and c-Jun signaling path-
ways causes that in the absence of NF-κB activity cellular 
susceptibility to TNF-induced apoptosis increases, whereas 
enforced activation of NF-κB protects against apoptosis [9].
Several adamantylamino-pyridine and -pyrimidine 
derivatives have TNF production-enhancing proper-
ties. 2-(1-adamantylamino)-6-methylpyridine (AdAMP) is 
the most potent of these adamantane derivatives, on some 
biological functions and TNF production by normal and neo-
plastic cells [10, 11]. In the previous study we demonstrated 
a strong TNF production-enhancing activity of AdAMP in 
human ovarian cancer cell line CAOV1 [12].
Adamantane derivatives were used for treatment of 
type A Influenza and the Parkinson’s disease [13, 14]. Anti-
proliferative activity of adamantane derivatives was found 
against murine leukemia cells (L1210), human T-lymphocyte 
cells (CEM), and cervix carcinoma cells (HeLa) [15].
NF-kB inhibitors constitute a heterogenic group of 
agents that can inhibit a proliferative pathway of TNF sign-
aling. The well-known NF-kB inhibitors are some antioxi-
dants, IkBa phosphorylation and/or degradation inhibitors, 
and proteasome inhibitors, i.e. N-a-tosyl-L-phenylalanine 
chloromethyl ketone (TPCK), pyrrolidine dithiocarbamate 
or MG-132 [16–18]. Some other agents like non-steroidal 
anti-inflammatory drugs, glucocorticoids, and cytokines 
(Il-10) have the activity of NF-kB inhibitors [18–20]. A revers-
ible 26S proteasome inhibitor, bortezomib, that has been 
recently approved by the Federal Drug Administration (FDA) 
and the European Regulatory Agency (EMEA) for the treat-
ment of multiple myeloma at least partly acts through the 
inhibition of NF-κB activity [21].
OBJECTIVES
In this study we tried to investigate the effect of N-a-to-
syl-L-phenylalanine chloromethyl ketone (TPCK) in combi-
nation with 2-(1-adamantylamino)-6-methylpyridine (Ad-
AMP) on human ovarian cell line CAOV-1 growth and to 
explain the possible mechanism of their action.
MATERIAL AND METHODS
Human ovarian cancer cells
The CAOV-1 line was a human ovarian cell line estab-
lished in Jagiellonian University in Krakow. 
The cell line was cultured in Dulbecco’sMEM with 4.5 g/L 
glucose, sodium pyruvate and Glutamax-1 (high glucose 
DMEM) supplemented with antibiotic-antimycotic, 50 µM 
2-mercaptoethanol and 10% fetal calf serum (FCS) (all from 
Gibco BRL, Life Technologies, Paisley, UK). Cells were main-
tained at 37°C in a humidified atmosphere containing 5% CO2.
Reagents
2-(1-adamantylamino)-6-methylpyridine (AdAMP) was 
synthesized at the Institute of Chemistry, Agriculture Uni-
versity of Warsaw, as described previously [22]. 
N-a-tosyl-L-phenylalanine chloromethyl ketone (TPCK) 
was purchased in Sigma (St. Louis, USA) . Both drugs were 
prepared as 100 mM stock solutions in DMSO and were 
diluted to the required concentration in culture medium.
Infliximab (Remicade®), a monoclonal antibody against 
TNF, was obtained from Janssen Biotech, Inc. (Belgium). The 
stock solution (10 mg/mL) was prepared in distilled water.
Crystal violet assay
The cytotoxic effect of TPCK and/or AdAMP on ovar-
ian cancer cells was tested in a standard crystal violet assay. 
The dye in this assay, crystal violet, stains DNA of adherent 
cells in monolayer. Cells that undergo cell death lose their 
adherence and are subsequently lost from the population 
of cells, reducing the amount of crystal violet staining in 
a culture.
Cells were incubated in 96-well plates (2 × 104/200 μL/well) 
with AdAMP (final concentrations: 25, 50, 100 and 200 μM) 
and TPCK (final concentrations: 8, 16, 32 and 64 μM), alone 
or in combination, for 24 h. In further experiments Infliximab 
at the concentration of 1, 10 or 100 µg/mL was added to the 
wells with AdAMP and TPCK and the cells were incubated in 
the same way. At the end of each incubation medium was 
removed and each well was washed with 200 µL of phos-
phate buffered saline (PBS). 50 µL of 0.1% water solution 
of crystal violet was added to each well for 10 minutes at 
room temperature. Then the plates were washed in distil-
lated water. Crystals of violet were dissolved by adding 
200 µL of 1% solution of sodium dodecyl sulfate (SDS) and 
shaking the plates. The plates were read on an ELISA reader 
(SLT-Labinstruments, Salzburg, Austria) using a 550 nm filter.
The means and standard deviations were determined 
for triplicate samples. The cytotoxic effect was expressed as 
309
Jacek Sieńko et al., Potentialization of TPCK cytotoxic activity by AdAMP
www. journals.viamedica.pl/ginekologia_polska
the relative viability and was calculated as follows: relative 
viability = [(experimental absorbance - background absor-
bance)/(absorbance of vehicle-treated cells — background 
absorbance) ×100.
Statistical analysis
Statistical evaluations were performed with Statis-
tica 7.0 software (StatSoft, Poland). Comparisons between 
groups of continuous outcomes were performed by Stu-
dent’s t-test after testing for normal distribution by the Kol-
mogorov-Smirnov test. P < .05 was considered significant.
Chou-Talalay analysis was performed to evaluate the 
strength of interaction between the drugs [23]. The result-
ing combination index (CI) was calculated. CI < 0.9 was 
considered to be synergism. Dose reduction index (DRI) 
— a measure of how many folds the dose of each drug in 
a synergistic combination may be reduced — was calculated 
using Calcusyn software.
RESULTS 
AdAMP and TPCK alone are cytotoxic to CAOV-1
To evaluate the cytotoxic effect of AdAMP and TPCK we 
incubated CAOV-1 cell line in 96-well plates as described 
above for 24 hours and assessed cell culture viability in crys-
tal violet assay. AdAMP was not cytotoxic to CAOV-1 line in 
the concentration of 25, 50 and 100 µM. The cytotoxic effect 
of AdAMP was statistically significant at the concentration 
of 200 µM (P < 0.01) (Fig. 1A). 
16, 32, 64 and 128 µM TPCK was cytotoxic to CAOV-1 line. 
TPCK at the concentration of 8 µM had no effect on the cell 
line viability (Fig. 1B).
Combinations of AdAMP and TPCK 
synergistically inhibit the growth of CAOV-1 cells 
in vitro
To determine if effectiveness of these two agents 
could be enhanced by applying them together we tested 
25, 50, 100 and 200 µM AdAMP combined with 16, 32, 
64 and 128 µM TPCK. AdAMP potentialized cytotoxic ac-
tivity of TPCK in the following concentrations: 50 µM Ad-
AMP + 64 µM TPCK, 100 µM AdAMP + 32–64 µM TPCK, 
200 µM AdAMP + 8–128 µM TPCK. Only the combination of 
200 µM AdAMP and 32 µM TPCK resulted in the synergistic 
interaction (CI = 0.598) (Fig. 3). Dose Reduction Index (DRI) 
for that combination of drugs was 1.946 for AdAMP and 
11.883 for TPCK.
TNF blocking by Infliximab does not reverse  
the synergistic effect of AdAMP and TPCK
To answer the question if potentialization/synergy in cy-
totoxic activity of AdAMP and TPCK is the result of enhanced 
TNF secretion associated with NF-κB pathway inhibition we 
blocked TNF with Infliximab in the concentration of 1, 10 or 
100 mg/L. As Infliximab was cytotoxic to CAOV-1 cell line in 
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Figure 1. Cytotoxic effect of AdAMP (A) and TPCK (B) on CAOV-1 cell 
line. Values are mean ± SD. *P < 0.05, #P < 0.01, ^P< 0.001
Figure 2. Cytotoxic effect of AdAMP and TPCK on CAOV-1 cell line. 
Values are mean ± SD. P value presents differences in series between 
cells non-stimulated and stimulated by AdAMP. *P < 0.001, #P < 0.0001
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the concentration of 100mg/L (relative viability 84.6 ± 4.0%, 
P < 0.0005) cellular viability was compared between the 
group incubated only with Infliximab or with Infliximab and 
AdAMP and TPCK. Infliximab did not reverse cytotoxic activ-
ity neither in 200 µM AdAMP and 32 µM TPCK nor in 100 µM 
AdAMP and 32 µM TPCK. 1, 10, 100 mg/L of Infliximab even 
enhanced cytotoxicity of 200 µM AdAMP and 32 µM TPCK 
and 10 mg/L of Infliximab had similar effect when added to 
100 µM AdAMP and 32 µM TPCK (Fig. 4).
DISCUSSION
A combination chemotherapy based on adjuvant mecha-
nisms of action of drugs has become the standard approach 
in the treatment of ovarian cancer. In target therapy the com-
plementary response to different agents usually includes 
interfering with different stages of cell signaling what in turn 
results in augmenting or silencing the desired reaction [24]. 
The study of Pazhang et al. is an example of a combina-
tion target therapy with NF-kB inhibitor [25]. The author 
showed synergistic effects of cytotoxic activity of NF-kB in-
hibitor, celastrol, and X-linked inhibitor of apoptosis protein 
(XIAP) inhibitor, embelin used in combination in an acute 
myeloid leukemia cell line, HL-60. He explained that the 
synergy of the two agents may be due to cross-talk between 
NF-κB and XIAP pathway of signal transduction.
In the present study we demonstrated that a NF-kB 
inhibitor, N-a-tosyl-L-phenylalanine chloromethyl ke-
tone (TPCK) is an active agent cytotoxic to CAOV-1 ovar-
ian cell line. Its cytotoxic activity can be augmented by 
2-(1-adamantylamino)-6-methylpyridine (AdAMP) in some 
concentrations. It is noteworthy that AdAMP potentialized 
cytotoxic activity of TPCK not only in the concentration in 
which AdAMP had cytotoxic activity alone (200 µM) but 
also in the concentration of 50–100 µM in which it was not 
cytotoxic to CAOV-1 cell line when applied as the only agent. 
We hypothesized that it could be at least partly due to the 
enhanced autocrine secretion of TNF associated with NF-kB 
pathway inhibition. This idea seemed to be supported by our 
previous study where we demonstrated a stimulation of TNF 
secretion by CAOV-1 cell line in the concentrations of 0.1 to 
less than 100 µM [12]. The real potential of CAOV-1 to secrete 
TNF in higher concentration of AdAMP is unknown as it is 
confounded by decreased viability of ovarian cancer cells. 
The synergistic effect of AdAMP and TPCK defined ac-
cording to Chou and Talalay [23] was observed only in the 
combination of 200 AdAMP AdAMP and 32 µM TPCK. How-
ever, it is necessary to emphasize that synergy can only be 
calculated if both drugs have cytotoxic activity. So, the CI 
had no application in the AdAMP concentrations of less 
than 200 µM that were “non-toxic” concentrations alone.
The experimental model with Infliximab added to Ad-
AMP and TPCK showed that neither the synergy between 
AdAMP and TPCK nor the augmentation of cytotoxic activity 
of TPCK by AdAMP can be entirely explained by TNF-depend-
ent apoptosis. Blocking TNF by Infliximab did not reverse the 
cytotoxic effect of AdAMP and TPCK what can suggest that 
TNF-induced-apoptosis with NF-κB pathway inhibition does 
not have be the dominating mechanism of action in this 
situation. On the other hand, Infliximab binds both soluble 
and membranous TNF and activates in vitro antibody- and 
complement-dependent cellular cytotoxicity by its Fc por-
tion [26]. Lugering et al. showed that TNF inhibition by 
Infliximab causes apoptosis in T-cells through the activa-
tion of caspase-8, -9, -3 and the increased transcription of 
the pro-apoptotic proteins Bax and Bak [27, 28]. It is not 
proved that this mechanism of action of Infliximab can be 
observed in ovarian cancer cells but we are aware that the 
potential of Infliximab to stimulate apoptosis could conceal 
the real action of AdAMP and TPCK in our model. In light 
of these investigations the influence of Infliximab both in 
cytotoxic and non-cytotoxic concentrations on the viability 
of CAOV-1 cell line treated with AdAMP and TPCK observed 
in our study can indirectly suggest that AdAMP and TPCK 
Figure 3. Cytotoxic interactions of AdAMP and TPCK. CI 
— combination index, CI was calculated from cytotoxic activity of 
drug combination. CI + 1SD < 0.9 is considered to be synergism
Figure 4. Influence of Infliximab on combined AdAMP and TPCK 
cytotoxicity in CAOV-1 cell line. Values are mean ± SD. P value 
presents differences between cells incubated only with Infliximab or 
with Infliximab and AdAMP and TPCK. *P < 0.01, #P < 0.001
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interact through the TNF signaling pathway. Unfortunately, 
multidirectional and dose-dependent TNF action makes it 
difficult to unambiguously prove one specific pathway of 
TNF signaling [29]. 
CONCLUSIONS 
We conclude that 2-(1-adamantylamino)-6-methylpy- 
ridine and N-a-tosyl-L-phenylalanine chloromethyl ketone 
are agents active against ovarian cancer cells and applied 
together reveal synergy or potentialization of cytotoxic 
activity. The molecular mechanism of that interactions re-
mains unclear, however, it is probable that they act through 
TNF signaling.
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